Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study.
Details
Serval ID
serval:BIB_032C8A9374F9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study.
Journal
Clinical Infectious Diseases
Working group(s)
ICE Prospective Investigators
Contributor(s)
Clara L., Sanchez M., Nacinovich F., Oses PF., Ronderos R., Sucari A., Thierer J., Casabé J., Cortes C., Altclas J., Kogan S., Spelman D., Athan E., Harris O., Kennedy K., Tan R., Gordon D., Papanicolas L., Eisen D., Grigg L., Street A., Korman T., Kotsanas D., Dever R., Jones P., Konecny P., Lawrence R., Rees D., Ryan S., Feneley MP., Harkness J., Jones P., Ryan S., Jones P., Ryan S., Jones P., Post J., Reinbott P., Ryan S., Gattringer R., Wiesbauer F., Andrade AR., de Brito£££Ana Cláudia Passos£££ AC. , Guimarães AC., Grinberg M., Mansur AJ., Siciliano RF., Strabelli TM., Vieira ML., de Medeiros Tranchesi RA. , Paiva MG., Fortes CQ., de Oliveira Ramos A., Ferraiuoli G., Golebiovski W., Lamas C., Santos M., Weksler C., Karlowsky JA., Keynan Y., Morris AM., Rubinstein E., Jones SB., Garcia P., Cereceda M., Fica A., Mella RM., Barsic B., Bukovski S., Krajinovic V., Pangercic A., Rudez I., Vincelj J., Freiberger T., Pol J., Zaloudikova B., Ashour Z., El Kholy A., Mishaal M., Rizk H., Aissa N., Alauzet C., Alla F., Campagnac C., Doco-Lecompte T., Selton-Suty C., Casalta JP., Fournier PE., Habib G., Raoult D., Thuny F., Delahaye F., Delahaye A., Vandenesch F., Donal E., Donnio PY., Michelet C., Revest M., Tattevin P., Violette J., Chevalier F., Jeu A., Sorel C., Tribouilloy C., Bernard Y., Chirouze C., Hoen B., Leroy J., Plesiat P., Naber C., Neuerburg C., Mazaheri B., Naber C., Neuerburg C., Athanasia S., Giannitsioti E., Mylona E., Paniara O., Papanicolaou K., Pyros J., Skoutelis A., Sharma G., Francis J., Nair L., Thomas V., Venugopal K., Hannan M., Hurley J., Gilon D., Israel S., Korem M., Strahilevitz J., Rubinstein E., Strahilevitz J., Casillo R., Cuccurullo S., Dialetto G., Durante-Mangoni E., Irene M., Ragone E., Tripodi MF., Utili R., Cecchi E., De Rosa F., Forno D., Imazio M., Trinchero R., Tebini A., Grossi P., Lattanzio M., Toniolo A., Goglio A., Raglio A., Ravasio V., Rizzi M., Suter F., Carosi G., Magri S., Signorini L., Baban T., Kanafani Z., Kanj SS., Yasmine M., Abidin I., Tamin SS., Martínez ER., Soto Nieto GI. , van der Meer JT. , Chambers S., Holland D., Morris A., Raymond N., Read K., Murdoch DR., Dragulescu S., Ionac A., Mornos C., Butkevich OM., Chipigina N., Kirill O., Vadim K., Vinogradova T., Edathodu J., Halim M., Lum LN., Tan RS., Lejko-Zupanc T., Logar M., Mueller-Premru M., Commerford P., Commerford A., Deetlefs E., Hansa C., Ntsekhe M., Almela M., Armero Y., Azqueta M., Castañeda X., Cervera C., Del Rio A., Falces C., Garcia-de-la-Maria C., Fita G., Gatell JM., Marco F., Mestres CA., Miró JM., Moreno A., Ninot S., Paré C., Pericas J., Ramirez J., Rovira I., Sitges M., Anguera I., Font B., Guma JR., Bermejo J., Bouza E., Fernández MA., Gonzalez-Ramallo V., Marín M., Muñoz P., Pedromingo M., Roda J., Rodríguez-Créixems M., Solis J., Almirante B., Fernandez-Hidalgo N., Tornos P., de Alarcón£££Arístides£££ A. , Parra R., Alestig E., Johansson M., Olaison L., Snygg-Martin U., Pachirat O., Pachirat P., Pussadhamma B., Senthong V., Casey A., Elliott T., Lambert P., Watkin R., Eyton C., Klein JL., Bradley S., Kauffman C., Bedimo R., Chu VH., Corey GR., Crowley AL., Douglas P., Drew L., Fowler VG., Holland T., Lalani T., Mudrick D., Samad Z., Sexton D., Stryjewski M., Wang A., Woods CW., Lerakis S., Cantey R., Steed L., Wray D., Dickerman SA., Bonilla H., DiPersio J., Salstrom SJ., Baddley J., Patel M., Peterson G., Stancoven A., Afonso L., Kulman T., Levine D., Rybak M., Cabell CH., Baloch K., Chu VH., Corey GR., Dixon CC., Fowler VG., Harding T., Jones-Richmond M., Pappas P., Park LP., Redick T., Stafford J., Anstrom K., Athan E., Bayer AS., Cabell CH., Chu VH., Corey GR., Fowler VG., Hoen B., Karchmer AW., Miró JM., Murdoch DR., Sexton DJ., Wang A., Bayer AS., Cabell CH., Chu V., Corey GR., Durack DT., Eykyn S., Fowler VG., Hoen B., Miró JM., Moreillon P., Olaison L., Raoult D., Rubinstein E., Sexton DJ.
ISSN
1537-6591 (Electronic)
ISSN-L
1058-4838
Publication state
Published
Issued date
2015
Volume
60
Number
5
Pages
741-749
Language
english
Abstract
BACKGROUND: The impact of early valve surgery (EVS) on the outcome of Staphylococcus aureus (SA) prosthetic valve infective endocarditis (PVIE) is unresolved. The objective of this study was to evaluate the association between EVS, performed within the first 60 days of hospitalization, and outcome of SA PVIE within the International Collaboration on Endocarditis-Prospective Cohort Study.
METHODS: Participants were enrolled between June 2000 and December 2006. Cox proportional hazards modeling that included surgery as a time-dependent covariate and propensity adjustment for likelihood to receive cardiac surgery was used to evaluate the impact of EVS and 1-year all-cause mortality on patients with definite left-sided S. aureus PVIE and no history of injection drug use.
RESULTS: EVS was performed in 74 of the 168 (44.3%) patients. One-year mortality was significantly higher among patients with S. aureus PVIE than in patients with non-S. aureus PVIE (48.2% vs 32.9%; P = .003). Staphylococcus aureus PVIE patients who underwent EVS had a significantly lower 1-year mortality rate (33.8% vs 59.1%; P = .001). In multivariate, propensity-adjusted models, EVS was not associated with 1-year mortality (risk ratio, 0.67 [95% confidence interval, .39-1.15]; P = .15).
CONCLUSIONS: In this prospective, multinational cohort of patients with S. aureus PVIE, EVS was not associated with reduced 1-year mortality. The decision to pursue EVS should be individualized for each patient, based upon infection-specific characteristics rather than solely upon the microbiology of the infection causing PVIE.
METHODS: Participants were enrolled between June 2000 and December 2006. Cox proportional hazards modeling that included surgery as a time-dependent covariate and propensity adjustment for likelihood to receive cardiac surgery was used to evaluate the impact of EVS and 1-year all-cause mortality on patients with definite left-sided S. aureus PVIE and no history of injection drug use.
RESULTS: EVS was performed in 74 of the 168 (44.3%) patients. One-year mortality was significantly higher among patients with S. aureus PVIE than in patients with non-S. aureus PVIE (48.2% vs 32.9%; P = .003). Staphylococcus aureus PVIE patients who underwent EVS had a significantly lower 1-year mortality rate (33.8% vs 59.1%; P = .001). In multivariate, propensity-adjusted models, EVS was not associated with 1-year mortality (risk ratio, 0.67 [95% confidence interval, .39-1.15]; P = .15).
CONCLUSIONS: In this prospective, multinational cohort of patients with S. aureus PVIE, EVS was not associated with reduced 1-year mortality. The decision to pursue EVS should be individualized for each patient, based upon infection-specific characteristics rather than solely upon the microbiology of the infection causing PVIE.
Pubmed
Web of science
Open Access
Yes
Create date
05/02/2015 15:46
Last modification date
20/08/2019 13:25
Usage data
